Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.59 – $1.01
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.6M | $0 | $1.04B | $243.7M | $481.4M | $463.8M | $407.2M | $262.6M |
| Cost of revenue | $0 | $0 | $241.4M | $106.8M | $203.0M | $159.5M | $167.1M | $217.8M |
| Gross profit | $12.6M | $0 | $797.4M | $136.9M | $278.4M | $304.3M | $240.2M | $44.8M |
| Gross margin | 100.0% | — | 76.8% | 56.2% | 57.8% | 65.6% | 59.0% | 17.1% |
| R&D | $850.2M | $1.40B | $1.40B | $1.30B | $614.2M | $527.8M | $134.7M | $303.5M |
| Operating income | −$1.03B | −$1.74B | −$1.09B | −$1.83B | −$912.1M | −$579.8M | −$91.7M | −$421.5M |
| EBITDA | −$1.02B | −$1.73B | −$1.20B | −$1.90B | −$849.7M | −$297.2M | −$26.2M | −$378.6M |
| Net income | −$1.75B | −$2.31B | −$1.22B | −$1.92B | −$902.7M | −$367.2M | −$91.2M | −$425.7M |
| Net margin | -13906.6% | — | -117.4% | -787.8% | -187.5% | -79.2% | -22.4% | -162.1% |
| EPS (diluted) | -2.79 | -2.39 | -1.17 | -1.65 | -0.77 | -0.29 | -0.07 | -0.31 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $460M | $-0.00 | $-0.01–$-0.00 | 1 |
| 2027 | $1.6B | $0.51 | $0.13–$1.45 | 1 |
| 2028 | $1.0B | $0.09 | $0.02–$0.26 | 1 |
Forward consensus · source: Financial Modeling Prep
CSTONE PHARMACEUTICALS
No one on the platform currently holds CSPHF.
No tracked institution reports a position in CSPHF as of their last filing.
No one on the platform has traded CSPHF yet.
| +0.00% |
| $2.0B |
| — |
| NURPFNeuren Pharmaceuticals Limited | $9.27 | +0.00% | $1.2B | — |
| ONTTFOxford Nanopore Technologies plc | $1.66 | +0.00% | $1.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.7× sales vs its 1.3× historical median P/S.
Fair value ≈ $1.08 · price $0.59 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.